Eikon Therapeutics, Inc. Common Stock

Eikon Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Millbrae, California, incorporated in 2019. It develops medicines for serious unmet medical needs. Its pipeline includes EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive anti-tumor immune responses; EIK1003 and EIK1004, selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers, with the brain-penetrant EIK1004 targeting brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a next-generation androgen receptor antagonist active against multiple clinically emergent androgen receptor variants.

Biotech & Genomic Medicine▲

Eikon Therapeutics to Join Russell 3000 Index Following Annual Reconstitution

Eikon Therapeutics will be added to the Russell 3000 Index after the market close on June 26, 2026, following the index's annual reconstitution. The clinical-stage biopharmaceutical company, which uses super-resolution microscopy and machine learning to discover drug targets for oncology and neurological diseases, confirmed the upcoming inclusion on June 25. Separately, BofA Securities lowered its price target for Eikon to $32 from $34 on June 3 while maintaining a Buy rating, citing steady advancement in development initiatives despite limited first-quarter updates.

EIKN ▲

Biotech & Genomic Medicine

Insider Monkey·78dRead more →